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Abstract 
Background: Late gadolinium enhancement (LGE) by cardiac magnetic resonance (CMR) 
may reveal myocardial fibrosis which is associated with adverse clinical outcomes in patients 
undergoing implantable cardioverter-defibrillator (ICD) placement. At the same time, 
transmural LGE in the posterolateral wall is related to nonresponse to conventional cardiac 
resynchronization therapy (CRT). Herein, the  aim was to assess the presence and 
determinants of LGE in CMR in heart failure (HF) with reduced ejection fraction.  
Methods: 67 patients were included (17.9% female, aged 45 [29–60] years), who underwent 
LGE-CMR and had left ventricular ejection fraction (LVEF) as determined by 
echocardiography.  
Results: In HF patients with LVEF ≤ 35% (n = 29), ischemic and non-ischemic patterns of 
LGE were observed in 51.7% and 34.5% of patients, respectively. In controls (n = 38), these 
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patterns were noted in 23.7% and 42.1% of patients, respectively. HF patients with LVEF ≤ 
35% and transmural LGE in the posterolateral wall (31.0%) were characterized by older age, 
coronary artery disease (CAD) and previous myocardial infarction (MI) (61 ± 6 vs. 49 ± 16 
years, p = 0.008, 100% vs. 40%, p = 0.003 and 78% vs. 25%, p = 0.014, respectively). In 
patients with LVEF ≤ 35%, LGE of any type, diagnosed in 86.2% of patients, was associated 
with CAD (68% vs. 0%, p = 0.02), while only trends were observed for its association with 
older age and previous MI (p = 0.08 and p = 0.12, respectively).  
Conclusions: Among HF patients with LVEF ≤ 35%, clinical factors including older age, 
CAD, and previous MI are associated with transmural LGE in the posterolateral wall, while 
CAD is associated with LGE. This data may have potential implications for planning ICD and 
CRT placement procedures.  
Key words: heart failure, late gadolinium enhancement, ischemic, cardiac magnetic 
resonance, transmural late gadolinium enhancement, cardiac resynchronization 
therapy, implantable cardioverter-defibrillator 
 
 
INTRODUCTION  
Appropriate patient evaluation for the placement of implantable cardioverter-
defibrillators (ICD) and cardiac resynchronization therapy (CRT) devices is important in the 
management of heart failure (HF) patients with reduced ejection fraction (HFrEF). In patients 
with an ischemic or non-ischemic etiology of HF, left ventricular ejection fraction (LVEF) ≤ 
35% continues to be used as a major criterion when considering patients for placement of an 
ICD in primary sudden cardiac death (SCD) prevention and to improve HF through CRT [1]. 
However, effective SCD risk stratification based solely on HF symptoms and LVEF has a 
number of limitations. At the same time, about 30% of patients do not respond to CRT [2, 3]. 
Cardiac magnetic resonance (CMR) imaging, especially with late gadolinium 
enhancement (LGE), is a valuable clinical tool in patients with left ventricular (LV) 
dysfunction [4, 5]. Gadolinium-based contrast agents accumulate and demonstrate delayed 
enhancement within areas of increased extracellular space such as fibrosis, thus enhancing 
areas of scarring [6]. The patterns of LGE help to differentiate between ischemic and non-
ischemic myocardial injury (Fig. 1A). Generally, ischemic myocardial injury tends to cause 
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LGE this is typically subendocardial or transmural [7]. Non-ischemic myocardial injury can 
be observed at the epicardium, in the mid-wall, or at insertion points [5, 7, 8]. Moreover, LGE 
has been found to predict clinical outcomes in selected patients undergoing ICD placement 
[9]. At the same time, response to conventional CRT is decreased in the presence of 
transmural scarring in the posterolateral LV segments (the place over which an LV lead is 
usually placed) [10]. 
The cardiac LV segmentation model published by the American Heart Association 
(AHA) divides the heart into 17 segments and is now widely used for the description of 
disease-affected myocardium [11]. These 17 segments have a reasonably consistent vascular 
supply from the main coronary arteries (Fig. 1B). The left anterior descending coronary artery 
(LAD) supplies segments 1, 2, 7, 8, 13, 14, and 17, the right coronary artery (RCA) supplies 
segments 3, 4, 9, 10, and 15, while the left circumflex coronary artery (LCx) supplies 
segments 5, 6, 11, 12, and 16 [11]. However, coronary arteries may be anomalous and their 
anatomy varies from patient to patient, creating a limitation of the AHA model [12–15].  
The main purpose of this study was to assess the presence and determinants of LGE in 
CMR in patients with HFrEF.  
 
METHODS  
Study population  
The study group included 67 patients (17.9% female, aged 45 [29–60] years) who 
underwent LGE-CMR at the Department of Diagnostic Imaging, University Hospital in 
Krakow between 2011 and 2015, and had data available on LVEF as determined by 
echocardiography. Further data were obtained from a structured medical documentation 
review (baseline patient demographics and clinical data including chronic diseases). 
Diagnosis of significant coronary artery disease (CAD) was based on coronary angiography 
(available in medical records of 36 patients) and was defined as coronary artery diameter 
stenosis of 50% or more, or previous cardiac revascularization (coronary angioplasty or 
coronary artery bypass grafting) [16]. Moreover, specifically a group of patients with LVEF ≤ 
35% was addressed as determined by echocardiography, because they are frequently 
considered for ICD and CRT placement according to the European Society of Cardiology 
guidelines [17]. The study was approved by the local ethics committee. 
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CMR imaging 
Cardiac magnetic resonance imaging was performed using a 1.5 Tesla scanner. 
Steady-state free precession cine images were acquired in the short-axis and two-, three-, and 
four-chamber views. LGE images were acquired 10–20 min after injection of 0.2 mL/kg 
gadoteridol (ProHance). Inversion recovery time was individually adapted to maximize 
contrast between regions of LGE and normal myocardium. The cardiac LV segmentation 
model published by the AHA was used for the description of disease-affected myocardial 
segments [11]. The distribution of LGE was also assessed according to territories supplied by 
coronary arteries as proposed in the AHA model [11]. Posterolateral LV segments were 
defined as basal inferior [4], basal inferolateral [5], mid inferior [10], and mid inferolateral 
[11] segments [10]. A transmural scar was defined as a hyperenhancement extending ≥ 51% 
of LV wall thickness in ≥ 1 of the LV segments [10].  
 
Statistical analysis  
Continuous variables are presented as means ± standard deviations or medians 
(interquartile ranges [IQR]), while categorical variables are given as numbers and 
percentages. Associations between categorical variables were assessed using the Pearson chi-
squared test or the Fisher exact test. Continuous variables between two groups were compared 
using the Student t-test or Mann-Whitney U test, as appropriate. The Spearman rank test was 
used to measure the degree of association between two continuous variables (if both of the 
variables tested had a non-normal distribution). Statistical significance was defined as a p 
value < 0.05. Statistical analyses were performed using IBM SPSS Statistics (version 24, IBM 
Corp., Armonk, NY, USA).  
 
RESULTS  
Study population  
Twenty nine patients were analyzed with HF and LVEF ≤ 35%, as determined by 
echocardiography, and 38 control patients with LVEF > 35%, also by echocardiography. 
Baseline characteristics of patients are shown in Table 1. In the whole group of patients only 
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ischemic or only non-ischemic patterns of LGE were observed in 24 (35.8%) and 26 (38.8%) 
patients, respectively. Six (9.0%) patients (only in the control group) had features of both 
ischemic and non-ischemic or a non-specific LGE pattern, while in 11 (16.4%) patients no 
LGE was observed. LVEF measured by echocardiography correlated with LVEF measured by 
CMR (R = 0.825, p < 0.001). Median LVEF measured by echocardiography was 47% (IQR 
25–60%), while median LVEF measured by CMR was 44% (IQR 25–54%). Results of 
coronary angiography were available in medical documentation from the University Hospital 
for 36 patients. The median time interval between CMR and coronary angiography was 7 days 
(IQR 3–24 days). 
 
Comparison of HF patients with LVEF of 35% or less and controls with LVEF > 35%  
Among patients with HF and LVEF ≤ 35%, as determined by echocardiography, an 
ischemic pattern of LGE was observed in 15 (51.7%) subjects, non-ischemic in 10 (34.5%) 
patients, while 4 (13.8%) patients had no LGE. In controls, an ischemic pattern of LGE was 
observed in 9 (23.7%) subjects, non-ischemic in 16 (42.1%), combined ischemic and non-
ischemic or a non-specific pattern in 6 (15.8%), while 7 (18.4%) had no LGE.  
There was no significant difference regarding the presence of LGE of any pattern 
between HF patients with LVEF ≤ 35% when compared to controls. However, the ischemic 
pattern of LGE was more prevalent in HF patients with LVEF ≤ 35% when compared to 
controls (Table 1). Moreover, in the first group of patients, transmural LGE was observed 
more frequently when compared with the remainder of the patients (44.8% vs. 13.2%, p = 
0.004). The presence of LGE of any pattern was observed more frequently in patients with 
LVEF ≤ 35% than in controls in the mid and apical third (75.9% vs. 44.7%, p = 0.01; 51.7% 
vs. 26.3%, p = 0.033; respectively), while there was no difference in observed LGE in the 
basal third between these two groups (Table 2). Interestingly, in the mid third LGE was 
observed more commonly in segments 8, 10, and 12, while in the apical third LGE was 
observed more commonly in segments 13, 15, and 16 in HF patients with LVEF ≤ 35% than 
in the control group (Table 2). 
In patients for whom coronary angiography data were available (n = 36) there was a 
trend towards a higher prevalence of CAD in HF patients with LVEF ≤ 35% than the 
remainder of the patients (63.6% vs. 35.7%, p = 0.102; Table 3). When individual coronary 
arteries were analyzed, only the LCx was more commonly affected by significant CAD in HF 
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patients with LVEF ≤ 35% when compared to controls (50.0% vs. 7.1%, p = 0.011). At the 
same time, when LGE was assessed in segments according to coronary artery distribution, 
there was a trend to more commonly observed LGE in segments supplied by the LAD in HF 
patients with LVEF ≤ 35% than in controls (68.2% vs. 35.7%, p = 0.056; Table 3). 
 
Assessment of HF patients with LVEF of 35% or less with or without LGE   
The vast majority of studied HF patients with LVEF ≤ 35% had observed LGE (n = 
25, 86.2%). LGE in HF patients with LVEF ≤ 35% was associated with CAD (68.0% vs. 
0.0%, p = 0.02), while only trends were observed for its association with older age and 
previous myocardial infarction (MI) (54.4 ± 13.4 vs. 41.0 ± 16.2, p = 0.08 and 48.0% vs. 
0.0%, p = 0.12, respectively). 
Patients with LVEF ≤ 35% and transmural LGE were older than the remainder of HF 
patients with LVEF ≤ 35% and no transmural LGE (60.1 ± 7.6 vs. 46.5 ± 15.7, p = 0.006; 
Table 4). CAD, MI, and the ischemic pattern of LGE were observed more commonly in 
patients with LVEF ≤ 35% and transmural LGE when compared with the remainder of 
patients with LVEF ≤ 35% and no transmural LGE (92.3% vs. 31.3%, p = 0.001; 84.6% vs. 
6.3%, p < 0.001; 100.0% vs. 12.5%, p < 0.001, as in Table 4). 
In HF patients with LVEF ≤ 35%, transmural LGE in the posterolateral wall (31%) 
was associated with older age, CAD, and previous MI (60.6 ± 6.3 vs. 49.0 ± 15.6 years, p = 
0.008, 100% vs. 40%, p = 0.003 and 77.8% vs. 25%, p = 0.014, respectively, Table 4). In a 
group of patients with LVEF ≤ 35% and transmural LGE in the posterolateral LV segments, 
the presence of an ischemic pattern of LGE was more prevalent when compared with the 
remaining HF patients with LVEF ≤ 35% and no observed transmural LGE in this region 
(100% vs. 30%, p = 0.001, Table 4).  
Patients with LVEF ≤ 35% and observed LGE in any LV segment from the 
posterolateral wall were older than patients with LVEF ≤ 35% and had no observed LGE in 
this region (61.5 ± 9.3 vs. 44.3 ± 13.2, p < 0.001). Among patients with LVEF ≤ 35% and 
observed LGE in any LV segment from the posterolateral wall, CAD was more frequently 
present than in the remaining patients with LVEF ≤ 35% and no observed LGE in this region 
(85.7% vs. 33.3%, p = 0.004; Table 5). The ischemic pattern of LGE was more common in 
patients with LGE in the posterolateral LV wall than in the group without LGE in this region 
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(78.6% vs. 26.7%, p = 0.005). Transmural LGE of any type was observed more commonly in 
HF patients with LGE in the posterolateral LV wall than in those without LGE in this region 
(71.4% vs. 20.0%, p = 0.005, Table 5).  
 
Comparison of patients with ischemic vs. non-ischemic pattern of LGE  
When patients with an ischemic (n = 24) vs. non-ischemic pattern (n = 26) of LGE 
were compared, CAD, previous MI, and dyslipidemia were more common in those with the 
ischemic pattern of LGE (Table 5). Patients with an ischemic pattern of LGE were more 
commonly admitted urgently to the hospital and had observed akinesia more commonly in 
CMR (79.2% vs. 46.2%, p = 0.016; 41.7% vs. 15.4%, p = 0.039, Table 5) when compared to 
patients with a non-ischemic LGE pattern. Interestingly, in all patients with an ischemic 
pattern of LGE (n = 24), LGE was observed more commonly only in apical segments when 
compared to patients with a non-ischemic pattern (70.8% vs. 30.8%, p = 0.005). Moreover, 
LGE of any pattern in the posterolateral wall was observed more commonly in patients with 
an ischemic LGE pattern when compared to patients with a non-ischemic LGE pattern (66.7% 
vs. 34.6%, p = 0.024). Similarly, transmural LGE, including that in the posterolateral wall, 
was observed more commonly in the first group when compared to the second group (Table 
5). Interestingly, only LVEF measured by CMR, but not by echocardiography, differed 
between patients with an ischemic and non-ischemic pattern of LGE (31.8 ± 12.7 vs. 45.5 ± 
16.3, p = 0.002; 31.0 [20.8–50.0] vs. 50.0 [23.8–61.3], p = 0.147, Table 5). 
 
DISCUSSION  
Cardiac magnetic resonance is the most accurate non-invasive method to evaluate 
myocardial necrosis and fibrosis, which helps in the identification of the underlying cause of 
LV dysfunction, and may provide important prognostic information [18–21]. Previous studies 
have shown the usefulness of CMR imaging qualitative assessment in the diagnostics of CAD 
[21–23]. It has been suggested that LGE may be useful in excluding significant CAD in some 
patients with new-onset LV dysfunction in whom there is no data suggestive of ischemic 
disease [22]. An analysis of LGE distribution is also valuable when differentiating between 
non-ischemic etiologies of LV dysfunction including dilated cardiomyopathy, cardiac 
sarcoidosis, myocarditis, hypertrophic cardiomyopathy, cardiac amyloidosis, and Anderson-
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Fabry disease [6]. However, it should be highlighted that an LGE pattern is not always 
specific for a particular disease and the inclusion of clinical information is crucial in the 
diagnostic process. 
Patient-specific coronary supply territories may be derived from magnetic resonance 
angiography, and these territories sometimes differ from those defined by the AHA model of 
coronary blood supply, which suggests that the 17-segmented model proposed by the AHA 
may be inaccurate [12, 24].  A greater prevalence of significant CAD in the LCx and more 
frequent LGE in segments supplied by the LAD in HF patients with LVEF ≤ 35%,has been 
observed. This highlights the potential discrepancies between coronary territories determined 
by coronary angiography and the presence of LGE on CMR. Moreover, this study suggests 
that LVEF as measured in CMR, but not in echocardiography, may be associated with 
patterns of LGE. Previous studies have shown a strong relationship between myocardial 
fibrosis and worsening of HF [25–27]. In patients with muscular dystrophy, Florian et al. [28] 
found a correlation between LVEF and LGE extent and a relationship between the LGE 
pattern and degree of LV systolic dysfunction. However, several studies involving patients 
with non-ischemic cardiomyopathy showed only a weak or no relationship between the 
presence of LGE or LGE volume and LV volume and function [29–32].  
LGE-CMR imaging could also be useful in the assessment of patients who meet 
criteria for CRT since absence of LGE is associated with greater CRT response [10]. Previous 
studies have found a significant correlation between total scar burden and non-response to 
CRT, and have proposed a dose–response type relationship in these groups, which may 
predict this outcome [33, 34]. A recent study including patients with dilated cardiomyopathy 
and CRT found that CRT-defibrillators provided a survival benefit over CRT-pacemakers 
only in patients with observed LGE [35]. Moreover, implantation of an LV lead over an area 
with transmural myocardial scarring may result in an ineffective CRT [10]. Thus, clinical 
determinants of transmural scarring in posterolateral LV segments were also searched for as 
its identification may lead to a qualification of patients to other forms of physiologic cardiac 
pacing, including His or para-His pacing, which would avoid potentially adverse outcomes 
related to right ventricular pacing [36]. Findings herein, suggest that clinical variables (older 
age, CAD, and previous MI) are associated with transmural posterolateral LGE. 
Cardiovascular risk stratification is important and could be improved by the use of 
biomarkers or data from Holter electrocardiogram recordings [37–39]. Some studies have 
demonstrated that the presence of LGE predicts poor clinical outcomes such as hospitalization 
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due to HF, fatal ventricular arrhythmias, and SCD, in patients with either an ischemic or non-
ischemic etiology of HF [8, 26, 40–44]. Non-ischemic HF etiology is one of the predictors of 
LVEF recovery [45]. However, a recently adjusted analysis has shown that major non-
ischemic fibrosis was related to worse clinical outcomes than MI [8]. The presence of LGE 
was found to be associated with appropriate ICD therapy. Among patients with dilated 
cardiomyopathy and LVEF ≤ 35%, ICD implantation was associated with a reduction in 
mortality only among those with LGE [9]. Thus, the present study is important as it explores 
the determinants of LGE presence. It was found that CAD is associated with LGE in HF 
patients with LVEF ≤ 35%, while previous MI and older age have a tendency to be associated 
with LGE in these patients. This is in line with observations by other investigators who 
demonstrated that the presence of LGE was significantly higher in patients with CAD. 
Moreover, they suggested that CMR is useful for classification of patients with new-onset HF 
and LV systolic dysfunction in relation to the presence or absence of CAD [22, 23]. LGE-
CMR imaging may provide independent prognostic information beyond LVEF. Thus, the 
analysis of LGE distribution may improve patient selection and scheduling for standard ICD 
implantation in primary prevention of SCD. The association between LGE and ventricular 
arrhythmias was observed both in studies on patients with mean LVEF ≤ 35% and in those 
with mean LVEF > 35% [43]. Importantly, many SCD occur in patients with EF > 35% [46]. 
Therefore, it may be hypothesized that patients with prevalent LGE and EF > 35% could also 
benefit from primary SCD prevention with ICD placement. 
 
Limitations of the study 
There are some limitations in this study. The current study is a retrospective analysis 
and includes a relatively small group of patients. There is potential over-representation of 
non-ischemic HF etiologies in the present cohort due to typical clinical scenarios in which 
CMR is most commonly used in clinical practice. Information on coronary angiography 
results was not available for all patients in their medical documentation. Coronary 
angiography and CMR were not always performed within few days apart. However, the 
median time interval between these studies was relatively short at 7 days (IQR 3–24 days). 
Detailed indications for the use of LGE-CMR before potential cardiovascular implantable 
electronic device implantation remain to be established in large prospective studies.  
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CONCLUSIONS  
Among HF patients with LVEF of 35% or less, clinical factors, including older age, 
CAD, and previous MI are associated with transmural LGE in the posterolateral wall, while 
CAD is associated with LGE. This data may have potential implications for planning ICD and 
CRT placement procedures. 
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Table 1. Baseline characteristics of heart failure (HF) patients with left ventricular ejection 
fraction (LVEF) ≤ 35% determined by echocardiography and controls with LVEF > 35%. 
Parameters Patients with HF and 
LVEF ≤ 35% (n = 29) 
Control patients (n = 
38) 
P 
Demographics 
Female sex 5 (17.2%) 7 (18.4%) 0.901 
Age [years] 57.0 (38.5–62.0) 35.0 (25.8–57.5) 0.004 
LVEF determined by 
echocardiography [%] 
23.3 ± 7.3 57.1 ± 8.8 < 0.001 
Diseases and risk factors 
HF 29 (100.0%) 13 (34.2%) < 0.001 
Myocardial infarction 12 (41.4%) 9 (23.7%) 0.122 
CAD 17 (58.6%) 15 (39.5%) 0.120 
Atrial fibrillation 6 (20.7%) 3 (7.9%) 0.160* 
Diabetes 6 (20.7%) 4 (10.5%) 0.309* 
Hyperlipidemia 13 (44.8%) 12 (31.6%) 0.267 
Hypertension 16 (55.2%) 13 (34.2%) 0.086 
Smoking 8 (27.6%) 8 (21.1%) 0.534 
CMR parameters 
CMR-LVEF [%] 24.7 (19.2–32.4) 51.8 (46.6–61.2) < 0.001 
CMR-LVEDV [mL] 271.3 (184.1–368.9) 170.9 (140.9–189.7) < 0.001 
CMR-LVESV [mL] 205.5 (121.5–280.3) 73.1 (61.7–93.6) < 0.001 
Ischemic LGE pattern only 15 (51.7%) 9 (23.7%) 0.018 
Any LGE 25 (86.2%) 31 (81.6%) 0.745* 
Any LGE in posterolateral 
LV segment 
14 (48.3%) 11 (28.9%) 0.105 
Any transmural LGE 13 (44.8%) 5 (13.2%) 0.004 
Any transmural LGE in 
posterolateral segment 
9 (31.0%) 3 (7.9%) 0.014 
*The Fisher exact test (exact significance, 2-sided). Values are presented as mean ± standard deviation or 
median (interquartile range) or number (percentage). CAD — coronary artery disease; CMR — cardiac magnetic 
resonance; LGE — late gadolinium enhancement; LVEDV — left ventricular end diastolic volume; LVESV — 
left ventricular end systolic volume  
 
 
Table 2. Comparison of localization of late gadolinium enhancement (LGE) between heart 
failure (HF) patients with left ventricular ejection fraction (LVEF) ≤ 35% determined by 
echocardiography and controls with LVEF > 35%.  
Segments Patients with HF and 
LVEF ≤ 35% (n = 29) 
Control patients 
(n = 38) 
P 
Any LGE pattern in basal third 18 (62.1%) 20 (52.6%) 0.440 
Basal anterior (1) 7 (24.1%) 5 (13.2%) 0.246 
Basal anteroseptal (2) 11 (37.9%) 9 (23.7%) 0.207 
Basal inferoseptal (3) 13 (44.8%) 12 (31.6%) 0.267 
Basal inferior (4) 10 (34.5%) 7 (18.4%) 0.134 
Basal inferolateral (5) 9 (31.0%) 5 (13.2%) 0.075 
Basal anterolateral (6) 5 (17.2%) 3 (7.9%) 0.278* 
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Any LGE pattern in mid third 22 (75.9%) 17 (44.7%) 0.01 
Mid anterior (7) 9 (31.0%) 6 (15.8%) 0.138 
Mid anteroseptal (8) 11 (37.9%) 6 (15.8%) 0.039 
Mid inferoseptal (9) 10 (34.5%) 7 (18.4%) 0.134 
Mid inferior (10) 11 (37.9%) 5 (13.2%) 0.018 
Mid inferolateral (11) 10 (34.5%) 7 (18.4%) 0.134 
Mid anterolateral (12) 10 (34.5%) 3 (7.9%) 0.006 
Any LGE pattern in apical third 15 (51.7%) 10 (26.3%) 0.033 
Apical anterior (13) 9 (31.0%) 4 (10.5%) 0.035 
Apical septal (14) 11 (37.9%) 7 (18.4%) 0.074 
Apical inferior (15) 11 (37.9%) 5 (13.2%) 0.018 
Apical lateral (16) 8 (27.6%) 2 (5.3%) 0.016* 
Apex (17) 3 (10.3%) 1 (2.6%) 0.308* 
*The Fisher exact test (exact significance, 2-sided). Values are presented as number 
(percentage).  
 
 
Table 3. Comparison in observed coronary artery disease in coronary angiography and 
segments with observed late gadolinium enhancement (LGE) according to coronary artery 
distribution between heart failure (HF) patients with left ventricular ejection fraction (LVEF) 
≤ 35% as determined by echocardiography and controls with LVEF > 35%. 
Significant coronary artery disease and LGE Patients with 
HF and LVEF 
≤ 35% (n = 22) 
Control 
patients 
(n = 14) 
P 
Significant coronary artery disease presence 
Any coronary artery  14 (63.6%) 5 (35.7%) 0.102 
Right coronary artery 10 (45.5%) 3 (21.4%) 0.143 
Left circumflex coronary artery 11 (50.0%) 1 (7.1%) 0.011* 
Left anterior descending coronary artery 10 (45.5%) 3 (21.4%) 0.143 
In one coronary artery 2 (9.1%) 4 (28.6%) 0.181* 
In two coronary arteries 6 (27.3%) 0 (0.0%) 0.062* 
In three or more coronary arteries 6 (27.3%) 1 (7.1%) 0.209* 
LGE location by coronary arteries territories 
LGE location in left anterior descending 
coronary artery territory 
15 (68.2%) 5 (35.7%) 0.056 
LGE location in right coronary artery territory 15 (68.2%) 8 (57.1%) 0.501 
LGE location in left circumflex coronary artery 
territory 
12 (54.5%) 4 (28.6%) 0.126 
LGE location in one coronary artery territory 5 (22.7%) 4 (28.6%) 0.712* 
LGE location in two coronary arteries territories 5 (22.7%) 5 (35.7%) 0.462* 
LGE location in three coronary arteries 
territories 
9 (40.9%) 1 (7.1%) 0.054* 
*The Fisher exact test (exact significance, 2-sided). Data on coronary angiography were 
available for 36 patients. Coronary angiography result was available in 36 patients. Values are 
presented as number (percentage).  
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Table 4. Differences between patients with and without any observed transmural late 
gadolinium enhancement (LGE) and between patients with and without any observed 
transmural LGE in posterolateral left ventricular segments, in heart failure (HF) patients with 
left ventricular ejection fraction (LVEF) ≤ 35% determined by echocardiography. 
 
*The Fisher exact test (exact significance, 2-sided). Values are presented as number 
(percentage).  
 
Parameters Transmural 
LGE 
present (n = 
13) 
No 
transmural 
LGE (n = 
16) 
P Transmural 
LGE in 
posterolater
al LV 
segments (n 
= 9) 
No 
transmural 
LGE in 
posterolateral 
LV segments 
(n = 20) 
P 
Demographics and other parameters 
Female 3 (23.1%) 2 (12.5%) 0.632* 1 (11.1%) 4 (20.0%) 1* 
Age [years] 60.1 ± 7.6 46.5 ± 15.7 0.006 60.6 ± 6.3 49.0 ± 15.6 0.008 
LVEF determined by 
echocardiography [%] 
24.6 ± 6.9 22.3 ± 7.6 0.405 22.6 ± 7.2 23.7 ± 7.4 0.702 
Urgent admission to 
hospital 
11 (84.6%) 7 (43.8%) 0.052* 8 (88.9%) 10 (50.0%) 0.096* 
Diseases and risk factors 
Coronary artery disease 12 (92.3%) 5 (31.3%) 0.001 9 (100.0%) 8 (40.0%) 0.003* 
Myocardial infarction 11 (84.6%) 1 (6.3%) < 0.001 7 (77.8%) 5 (25.0%) 0.014* 
Diabetes 2 (15.4%) 4 (25.0%) 0.663* 0 (0.0%) 6 (30.0%) 0.137* 
Hypertension 8 (61.5%) 8 (50.0%) 0.534 5 (55.6%) 11 (55.0%) 1* 
Dyslipidemia 8 (61.5%) 5 (31.3%) 0.103 5 (55.6%) 8 (40.0%) 0.688* 
Smoking 3 (23.1%) 5 (31.3%) 0.697* 2 (22.2%) 6 (30.0%) 1* 
Atrial fibrillation 3 (23.1%) 3 (18.8%) 1* 3 (33.3%) 3 (15.0%) 0.339* 
CMR parameters 
CMR-LVEF [%] 24.0 (18.3–
32.4) 
24.8 (20.9–
36.1) 
0.809 22.8 ± 7.9 29.0 ± 10.4 0.120 
CMR-LVEDV [mL] 281.9 ± 
124.8 
284.0 ± 
100.7 
0.959 332.5 ± 
117.7 
260.8 ± 101.6 0.105 
CMR-LVESV [mL] 212.0 ± 
105.8 
205.3 ± 
99.7 
0.863 256.3 ± 97.7 186.7 ± 96.6 0.085 
Akinesia 6 (46.2%) 4 (25.0%) 0.270* 4 (44.4%) 6 (30.0%) 0.675* 
Dyskinesia 7 (53.8%) 8 (50.0%) 0.837 5 (55.6%) 10 (50.0%) 1* 
Hypokinesia 13 (100.0%) 14 (87.5%) 0.488* 9 (100.0%) 18 (90.0%) 1* 
Ischemic LGE pattern 
only 
13 (100.0%) 2 (12.5%) < 0.001 9 (100.0%) 6 (30.0%) 0.001* 
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Table 5. Differences between patients with and without observed any late gadolinium enhancement (LGE) in posterolateral left ventricular 
segments in heart failure (HF) patients with left ventricular ejection fraction (LVEF) ≤ 35% as determined by echocardiography and comparison 
of patients with ischemic and non-ischemic pattern of LGE.  
Parameters LGE in 
posterolateral 
wall (n = 14) 
No LGE in 
posterolateral 
wall (n = 15) 
P Ischemic LGE pattern 
only (n = 24)# 
Non-ischemic LGE 
pattern only (n = 26)# 
P 
Demographics and other parameters 
Female 1 (7.1%) 4 (26.7%) 0.330* 5 (20.8%) 4 (15.4%) 0.721* 
Age [years] 61.5 ± 9.3 44.3 ± 13.2 < 0.001 60.0 (53.5–68.0) 38.0 (27.8–57.5) 0.001 
LVEF determined by echocardiography 
[%] 
21.9 ± 7.5 24.7 ± 7.0 0.294 31.0 (20.8–50.0) 50.0 (23.8–61.3) 0.147 
Urgent admission to hospital 10 (71.4%) 8 (53.3%) 0.316 19 (79.2%) 12 (46.2%) 0.016 
Diseases and risk factors 
CAD 12 (85.7%) 5 (33.3%) 0.004 21 (87.5%) 9 (34.6%) < 0.001 
Myocardial infarction 8 (57.1%) 4 (26.7%) 0.096 18 (75.0%) 1 (3.8%) < 0.001 
Diabetes 4 (28.6%) 2 (13.3%) 0.390* 7 (29.2%) 3 (11.5%) 0.164* 
Hypertension 10 (71.4%) 6 (40.0%) 0.089 15 (62.5%) 10 (38.5%) 0.089 
Dyslipidemia 8 (57.1%) 5 (33.3%) 0.198 15 (62.5%) 6 (23.1%) 0.005 
Smoking 3 (21.4%) 5 (33.3%) 0.682* 4 (16.7%) 8 (30.8%) 0.243 
Atrial fibrillation 4 (28.6%) 2 (13.3%) 0.390 5 (20.8%) 3 (11.5%) 0.456* 
CMR parameters 
CMR-LVEF [%] 24.6 ± 8.0 29.5 ± 11.4 0.194 31.8 ± 12.7 45.5 ± 16.3 0.002 
CMR-LVEDV [mL] 313.4 ± 113.5 254.8 ±102.4 0.155 214.9 (169.1–322.4) 179.7 (153.3–268.9) 0.236 
CMR-LVESV [mL] 229.5 ± 106.5 188.6 ± 94.2 0.283 140.3 (114.6–260.1) 80.8 (61.5–169.0) 0.011 
Akinesia 7 (50.0%) 3 (20.0%) 0.128* 10 (41.7%) 4 (15.4%) 0.039 
Dyskinesia 8 (57.1%) 7 (46.7%) 0.573 10 (41.7%) 7 (26.9%) 0.272 
Hypokinesia 14 (100.0%) 13 (86.7%) 0.483* 21 (87.5%) 18 (69.2%) 0.119 
Any transmural LGE 10 (71.4%) 3 (20.0%) 0.005 17 (70.8%) 1 (3.8%) < 0.001 
Any transmural LGE in posterolateral LV 
segment 
9 (64.3%) 0 (0.0%) < 0.001* 11 (45.8%) 1 (3.8%) 0.001 
#Six patients with both ischemic and non-ischemic or non-specific pattern of LGE and 11 patients with no LGE were excluded from these sub analyses. *Fisher’s exact test 
(exact significance, 2-sided). Values are presented as number (percentage). For abbreviations see Table 1. 
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Figure 1. The patterns of late gadolinium enhancement reflecting ischemic and non-ischemic 
myocardial injury (A) and assignment of the 17 myocardial segments to the territories of the 
coronary arteries (B). Based on references [7, 11]; LAD — left anterior descending coronary 
artery; LCx — left circumflex coronary artery; LGE — late gadolinium enhancement; RCA 
— right coronary artery. 
 


